Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3143)
All Articles published online
|
Jan 28, 2009 (publication date) through Feb 11, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15(4): 449-456 [PMID: 19152449 DOI: 10.3748/wjg.15.449] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i4/449.htm |
| Number | Citing Articles |
| 1 |
Efstathios T. Pavlidis, Konstantinos D. Ballas, Nikolaos G. Symeonidis, Kyriakos Psarras, Georgios Koliakos, Kokona Kouzi-Koliakos, Konstantina Topouridou, Savas F. Rafailidis, Theodoros E. Pavlidis, Georgios N. Marakis, Athanasios K. Sakantamis. The effect of bevacizumab on colon anastomotic healing in rats. International Journal of Colorectal Disease 2010; 25(12): 1465 doi: 10.1007/s00384-010-1039-x
|
| 2 |
Haoyan Guo, Longjie Miao, Chengdong Yu. The efficacy of targeted therapy and/or immunotherapy with or without chemotherapy in patients with colorectal cancer: A network meta-analysis. European Journal of Pharmacology 2025; 988: 177219 doi: 10.1016/j.ejphar.2024.177219
|
| 3 |
Nasir A. Khan, Mark O. Baerlocher, Richard J.T. Owen, Stephen Ho, John R. Kachura, Stephen T. Kee, Dave M. Liu. Ablative Technologies in the Management of Patients with Primary and Secondary Liver Cancer: An Overview. Canadian Association of Radiologists Journal 2010; 61(4): 217 doi: 10.1016/j.carj.2009.12.009
|
| 4 |
M. Ducreux, A. Adenis, J.-P. Pignon, E. François, B. Chauffert, J.L. Ichanté, E. Boucher, M. Ychou, J.-Y. Pierga, C. Montoto-Grillot, T. Conroy. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). European Journal of Cancer 2013; 49(6): 1236 doi: 10.1016/j.ejca.2012.12.011
|
| 5 |
Francesco Montagnani, Antonella Chiriatti, Sara Licitra, Camillo Aliberti, Giammaria Fiorentini. Differences in Efficacy and Safety Between Capecitabine and Infusional 5-Fluorouracil When Combined With Irinotecan for the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2010; 9(4): 243 doi: 10.3816/CCC.2010.n.036
|
| 6 |
Fabio A.B. Schutz, Denis L.F. Jardim, Youjin Je, Toni K. Choueiri. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. European Journal of Cancer 2011; 47(8): 1161 doi: 10.1016/j.ejca.2011.03.005
|
| 7 |
Qiaoling Sun, Jinghong Zhou, Zheng Zhang, Mingchuan Guo, Junqing Liang, Feng Zhou, Jingwen Long, Wei Zhang, Fang Yin, Huaqing Cai, Haibin Yang, Weihan Zhang, Yi Gu, Liang Ni, Yang Sai, Yumin Cui, Meifang Zhang, Minhua Hong, Junen Sun, Zheng Yang, Weiguo Qing, Weiguo Su, Yongxin Ren. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biology & Therapy 2014; 15(12): 1635 doi: 10.4161/15384047.2014.964087
|
| 8 |
Fei Dai, Lixing Shu, Yangfang Bian, Zhuo Wang, Zhangwei Yang, Wengong Chu, Shen Gao. Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials. Clinical Drug Investigation 2013; 33(11): 779 doi: 10.1007/s40261-013-0125-6
|
| 9 |
Irena Ilic, Slobodan Jankovic, Milena Ilic, Yu-Jia Chang. Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis. PLOS ONE 2016; 11(8): e0161912 doi: 10.1371/journal.pone.0161912
|
| 10 |
Wang Ming, Zheng Xiaofeng, Ruan Xiaojiao, Ye Bailiang, Cai Long, Lin Feizhuan, Tu Jinfu, Jiang Feizhao, Li Shaotang. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis. Chinese Medical Journal 2014; 127(3): 538 doi: 10.3760/cma.j.issn.0366-6999.20132241
|
| 11 |
Yuan Su, Wei-Bing Yang, Shi Li, Zhi-Jian Ye, Huan-Zhong Shi, Qiong Zhou, Yihai Cao. Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature. PLoS ONE 2012; 7(4): e35629 doi: 10.1371/journal.pone.0035629
|
| 12 |
Shuai Liu, Lu Lu, Feng Pan, Chunsheng Yang, Jing Liang, Jinfeng Liu, Jian Wang, Rong Shen, Fu-Ze Xin, Nan Zhang. Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2022; 29(1): 25 doi: 10.3727/096504022X16427607626672
|
| 13 |
Iago Dillion Lima Cavalcanti. Chemotherapy Protocols and Infusion Sequence. 2022; : 125 doi: 10.1007/978-3-031-10839-6_5
|
| 14 |
Linda S. Elting, Yu-Chia Chang, Pratibha Parelkar, Christine B. Boers-Doets, Marisol Michelet, Guido Hita, Tanya Rouleau, Catherine Cooksley, Josiah Halm, Madhuri Vithala, Paolo Bossi, Carmen Escalante, Michael T. Brennan. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Supportive Care in Cancer 2013; 21(11): 3243 doi: 10.1007/s00520-013-1821-8
|
| 15 |
Tianshu Ren, Shu Wang, Zexu Shen, Chang Xu, Yingshi Zhang, Fuhai Hui, Xingshun Qi, Qingchun Zhao. Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. Drug Safety 2021; 44(1): 29 doi: 10.1007/s40264-020-00997-2
|
| 16 |
Fan Zhou, Jiang-Hua Shao, Lin-Quan Wu, Xiang-Bao Yin, Xin Yu. Risk of Serious Neutropenic Events in Cancer Patients Treated with Bevacizumab: A Meta-analysis. Asian Pacific Journal of Cancer Prevention 2013; 14(4): 2453 doi: 10.7314/APJCP.2013.14.4.2453
|
| 17 |
C. P. Escalante, Y. C. Chang, K. Liao, T. Rouleau, J. Halm, P. Bossi, S. Bhadriraju, N. Brito-Dellan, S. Sahai, S. W. Yusuf, A. Zalpour, L. S. Elting. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Supportive Care in Cancer 2016; 24(9): 4057 doi: 10.1007/s00520-016-3310-3
|
| 18 |
Elena Galfrascoli, Sheila Piva, Michela Cinquini, Antonio Rossi, Nicla La Verde, Annalisa Bramati, Anna Moretti, Andrea Manazza, Giovanna Damia, Valter Torri, Gaetana Muserra, Gabriella Farina, Marina Chiara Garassino. Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis. Digestive and Liver Disease 2011; 43(4): 286 doi: 10.1016/j.dld.2010.10.010
|
| 19 |
Yu Song, Qianqian Mao, Manling Zhou, Cheng-Jiang Liu, Li Kong, Ting Hu. Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterology 2024; 24(1) doi: 10.1186/s12876-024-03134-w
|
| 20 |
Dimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, Anastasia G Eleftheraki, Ioannis Xanthakis, Thomas Makatsoris, Epaminondas Samantas, Ioannis Varthalitis, Pavlos Papakostas, Nikitas Nikitas, Christos N Papandreou, George Pentheroudakis, Eleni Timotheadou, Angelos Koutras, Joseph Sgouros, Dimitrios Bafaloukos, George Klouvas, Theofanis Economopoulos, Konstantinos N Syrigos, George Fountzilas. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-271
|
| 21 |
Fan-Jie Qu, Shuang Wu, Yan Kong. Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report. World Journal of Gastrointestinal Oncology 2023; 15(5): 902-910 doi: 10.4251/wjgo.v15.i5.902
|
| 22 |
F.A.B. Schutz, Y. Je, G.R. Azzi, P.L. Nguyen, T.K. Choueiri. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Annals of Oncology 2011; 22(6): 1404 doi: 10.1093/annonc/mdq587
|
| 23 |
M. R. Rutledge, Dominic A. Solimando, J. Aubrey Waddell. Caplri (XelIri) Regimen for Advanced and Metastatic Colorectal or Esophogastric Cancer. Hospital Pharmacy 2012; 47(2): 98 doi: 10.1310/hpj4702-98
|
| 24 |
Tung Hoang, Dae Kyung Sohn, Byung Chang Kim, Yongjun Cha, Jeongseon Kim. Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.756214
|
| 25 |
Tobias Engel Ayer Botrel, Luciana Gontijo de Oliveira Clark, Luciano Paladini, Otávio Augusto C. Clark. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2734-y
|
| 26 |
Xing-Lin Chen, Ying-Hong Lei, Cun-Fei Liu, Qun-Fang Yang, Pei-Yuan Zuo, Cheng-Yun Liu, Chang-Zhong Chen, Yu-Wei Liu, Luis Eduardo M. Quintas. Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis. PLoS ONE 2013; 8(6): e66721 doi: 10.1371/journal.pone.0066721
|
| 27 |
Shaotang Li, Pan Chi. Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer. BioDrugs 2011; 25(1): 43 doi: 10.2165/11584680-000000000-00000
|
| 28 |
R López, M Salgado, M Reboredo, C Grande, J C Méndez, M Jorge, C Romero, G Quintero, J de la Cámara, S Candamio. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. British Journal of Cancer 2010; 103(10): 1536 doi: 10.1038/sj.bjc.6605938
|
| 29 |
M. Degirmenci, B. Karaca, G. Gorumlu, R. Durusoy, G. Demir Piskin, M. T. Bozkurt, Y. Cirak, D. Tunali, B. Karabulut, U. A. Sanli, R. Uslu. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Medical Oncology 2010; 27(3): 585 doi: 10.1007/s12032-009-9253-5
|
| 30 |
Hyun Joo Jang, Bum Jun Kim, Jung Han Kim, Hyeong Su Kim. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget 2017; 8(42): 73009 doi: 10.18632/oncotarget.20314
|
| 31 |
Hidetoshi Shindoh, Kohnosuke Nakano, Takemi Yoshida, Masaki Ishigai. Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans - toxicological implications. The Journal of Toxicological Sciences 2011; 36(4): 411 doi: 10.2131/jts.36.411
|